Activity

5% CI .83 – 1.43, P=.57). CONCLUSIONS Patients with HIV/AIDS undergoing AV access creation have similar outcomes to those without HIV, including long-term survival. Patients with HIV/AIDS had fewer traditional ESRD risk factors compared to non-HIV patients. Our findings show that contemporary approach for creation and management of AV access in patients with HIV/AIDS should be continued, however, further research is needed to identify risk factors in this population. BACKGROUND Contrast induced nephropathy is a possible adverse event in fenestrated endografting (FEVAR). Automated CO2-angiography has been proposed as an alternative to iodinated contrast media (ICM) for standard endovascular aneurysm repair; however, its use in FEVAR has not been investigated yet. The aim of this study was to analyze the possibility of reducing the amount of procedural ICM during FEVAR by combining CO2 with intraprocedural 3D preoperative computed tomography angiography overlaid onto 2D live fluoroscopic images (fusion imaging – FI). METHODS Between January and April 2018, juxta/para-renal and type-IV thoracoabdominal aneurysms undergoing FEVAR with a CO2+FI protocol were prospectively collected and compared with FEVAR cases treated with standard procedural imaging (ICM+FI) between June and December 2017. Pre, intra and post-operative data were analyzed. Amount of ICM, procedural/fluoroscopy time, total radiation dose (DAP), endoleaks (EL) and technical success (TS) – defined as absence of increase of post-operative creatinine was smaller in CO2+FI than ICM+FI [0.09 (IQR0.03) vs 0.3 (IQR0.4) mg/dL; P.04]. The median hospitalization time was shorter in CO2+FI [5 (IQR1) vs 8 (IQR4) days; P.002]. No reintervention was necessary at 30-day and 6-month follow-up in either group. CONCLUSIONS CO2+FI is safe and effective in FEVAR and allows the amount of ICM to be significantly reduced, leading to shorter hospitalization time and better renal function preservation at 30 days. TS, procedure/fluoroscopy time, radiation dose and 6-month reinterventions are comparable with standard ICM imaging protocol for FEVAR. Based on this preliminary experience, CO2+FI may be proposed as an effective tool to reduce the overall amount of procedural ICM, with consequent benefits on perioperative renal function. OBJECTIVE To evaluate the 1-year safety and effectiveness outcomes associated with the PQ Bypass DETOUR System for the percutaneous bypass of long-segment femoropopliteal occlusive disease. METHODS This prospective, single-arm, multicenter trial enrolled patients with long-segment femoropopliteal arterial disease. The DETOUR System percutaneously deploys modular stent-grafts to bypass femoropopliteal lesions through a transvenous route. Eligible patients included those with Trans-Atlantic Inter-Society Consensus C and D lesions >100 mm in length. The primary safety endpoint was the major adverse event (MAE) rate through 1 month, defined as the composite of death, clinically driven target vessel revascularization (CD-TVR), or major amputation. The primary effectiveness endpoint was stent-graft patency through 6 months, defined as freedom from stenosis ≥50%, occlusion, or CD-TVR. RESULTS Over a 24-month period, 78 patients (82 limbs) were enrolled. The average core laboratory measured lesion length was 371 ± 55 the femoropopliteal vein level. There were no instances of pulmonary embolism. CONCLUSIONS The 1-year results from the DETOUR I trial shows the PQ Bypass DETOUR System is a safe and effective percutaneous treatment option for patients with longer, severely calcified, above the knee femoropopliteal lesions. TRIAL REGISTRATION NCT02471638. OBJECTIVES Retrograde open mesenteric stenting (ROMS) is an alternative to traditional bypass in patients who present with acute mesenteric ischemia (AMI). However, there is a paucity of data comparing outcomes of ROMS to other open surgical approaches. This study represents the largest single-institution experience with ROMS and aims to compare outcomes of ROMS with conventional mesenteric bypass. METHODS All patients who presented with AMI from 2008 to 2019 and were treated with either ROMS or mesenteric bypass were included in the study. Patient, procedure, and outcome variables were compared. Bypass and ROMS patients were compared using univariate statistics. RESULTS A total of 34 patients who presented with acute mesenteric ischemia needing bypass were included in the study. 16 underwent mesenteric bypass, while 18 underwent ROMS. ROMS patients tended to be older and had higher rates of comorbidities than bypass patients. Bindarit Inflamm inhibitor Bypass patients were more likely to have a history of chronic mesenteric symptoms (68.8% vs. 27.8%, p-value = .019). Bypass procedures also took longer than ROMS procedures (302 vs. 189 minutes, p-value = less then .01). The majority of ROMS were not performed in a hybrid room (77.8%). Within one year, one ROMS stent thrombosed requiring later mesenteric bypass. In the bypass group, one conduit thrombosed ultimately resulting in perioperative death, and one bypass anastomosis stenosed requiring angioplasty. Complication, unanticipated reintervention, and mortality rates were otherwise similar between groups. CONCLUSIONS Complication, reintervention, and mortality rates following ROMS are similar to mesenteric bypass in the setting of AMI. Given similar postoperative outcomes, and ability to perform these procedures in a conventional operating room but with significantly shorter operative times, ROMS should be considered a first line option in acute situations when the operator is comfortable performing the procedure. OBJECTIVE To evaluate the safety and effectiveness of single ProGlide use per bilateral access site for Endovascular Aneurysm Repair (EVAR) of Abdominal Aortic Aneurysms (AAA). METHODS A retrospective cohort study was performed for all elective percutaneous EVARs from November 2015-December 2017 at the QEII Health Sciences Centre, Nova Scotia. Exposure of interest was number of ProGlides used per access site, dichotomized into bilateral single ProGlide closure vs non-single ProGlide closure on at least one femoral arteriotomy. Outcomes included Vascular Access Site and Access Related Complications 2 (VARC2) and Bleeding Academic Research Consortium (BARC) criteria. Groups were compared with Fisher exact test, ANOVA or Wilcoxon rank sum, as appropriate. Logistic regression was used to compare the effect of single ProGlide use on VARC2 and BARC. RESULTS A total of 131 cases were included, of which 116 had bilateral single ProGlide for access closure. Baseline characteristics including co-morbidities and smoking status were compared amongst groups.